Acne vulgaris affects a large proportion of adolescents and young adults and can lead to long-term scarring and psychological distress. Its pathogenesis involves excessive sebum production, bacterial ...

Here's what dermatologists have to say.

Ascletis Pharma has reported positive topline Phase III results showing that denifanstat (ASC40), a first-in-class oral FASN inhibitor for moderate-to-severe acne, delivered a favorable long-term ...

A New Jersey man won a $25 million verdict after he alleged that Roche (RHHBY.PK)'s acne drug Accutane gave him an inflamatory bowel disorder that required the removal of his colon. The verdict raises ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

View post: Matt Damon & Ben Affleck’s Explosive Return: Why Netflix’s ‘The Rip’ Is 2026’s Must-Watch Action Thriller What if the key to human limb regeneration wasn’t buried in sci-fi dreams—but ...

WASHINGTON — It will be tougher next year for women to get a prescription for the acne drug Accutane, under a new program announced Wednesday by the Food and Drug Administration. Accutane, used to ...

"As many as half of the people who develop schizophrenia had previously attended child and adolescent mental health services for other mental health problems. At present, though, we don't have any ...

LONDON (Reuters) - People with severe acne have an increased risk of suicide, researchers said Thursday in a study adding fuel to a debate about whether acne drugs such as Roche's Accutane prompt ...